A Phase 1/2 interventional study of axatilimab in Chronic Graft-versus-host-disease, sponsored by Syndax Pharmaceuticals. Completed at 11 sites in United States. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2025-09-15.
Sponsored by Syndax Pharmaceuticals · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing axatilimab in Bronchiolitis Obliterans Syndrome — 5 open to participants now, 9 under way, 3 of them phase 3. axatilimab · Bronchiolitis Obliterans Syndrome.
Among the 10 studies testing axatilimab in Bronchiolitis Obliterans Syndrome, this one is the 7th largest by enrollment, is the only one that started in 2018, is one of 2 in phase 1/2, and was the 1st registered.
714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.
Browse Bronchiolitis Obliterans Syndrome studies →5 of the 10 studies testing axatilimab in Bronchiolitis Obliterans Syndrome are open now, in 12 countries. Recruiting first, the newest first:
Incyte Corporation · Sites in United States, Belgium, Germany and 3 more countries
Ages 2–17
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+
University of Miami · Sites in United States
Ages 12+
Incyte Corporation · Sites in United States, Australia, Austria and 10 more countries
Ages 12+
Syndax Pharmaceuticals · Sites in United States, Australia, Belgium and 13 more countries
Ages 2+
By country, each count listing its studies:
axatilimab: first FDA approval 2024 (NIKTIMVO). What it is approved for, and how studies give it, is on its page →
Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.
This study: 6 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 3
First in 2018; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is below the median of 50 across 565 interventional studies indexed under Bronchiolitis Obliterans Syndrome.
Median enrollment 50 across the 10 interventional studies. Of the 1 that completed or were terminated, 1 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 10 have an industry lead sponsor. The 5 most frequent:
Syndax Pharmaceuticals is the lead sponsor of 31 studies on the registry; 4 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 6 (50%) have results posted.
Syndax Pharmaceuticals has 2 studies filed under Bronchiolitis Obliterans Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies testing axatilimab in Bronchiolitis Obliterans Syndrome that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585774Phase 3Incyte CorporationA Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | 2027-09-28 |
| NCT06843408Incyte CorporationA Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD | 2027-01-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies testing axatilimab in Bronchiolitis Obliterans Syndrome, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1/2, Open-label, Dose Escalation study to investigate axatilimab in participants with active chronic graft versus host disease (cGVHD).
This is a dose escalation and dose expansion study in participants with active cGVHD who have received at least 2 lines of prior therapy.
Key Inclusion Criteria:
Participants with active cGVHD who have received at least 2 . Participants 18 or older with active cGVHD who have erythematous rash involving >25% body surface area or a NIH mouth score of >4 must have received prior ibrutinib therapy.
a. Active cGVHD is defined as the presence of signs and symptoms of cGVHD per 2014 NIH Consensus Development Project on Criteria for Clinical trials in cGVHD.
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Escalating dose levels of axatilimab to establish the optimal biologic dose (OBD) and recommended Phase 2 dose (RP2D). Intravenous (IV) infusion; axatilimab at a dose of 0.15 milligrams (mg)/kilogram (kg) to 3 mg/kg.
Drug: axatilimab
Phase 2, dose expansion, is an open-label design, evaluating the 1 mg/kg dose in a larger sample size. IV infusion; axatilimab at a dose of 1 mg/kg.
Drug: axatilimab
axatilimab is a high affinity antibody targeting the colony stimulating factor 1 receptor (CSF-1R). CSF-1R signaling has been demonstrated in nonclinical studies to be the key regulatory pathway involved in the expansion and infiltration of donor derived macrophages that mediate the disease processes involved in cGVHD.
Also known as: Niktimvo, SNDX-6352
Phase 1: Number of Participants With DLTs
A DLT was defined as the occurrence of any protocol-specified event within the first 28 days from the first dose of SNDX-6352 or administration of the third dose (Cycle 2 Day 1), whichever is later (from Cycle 1 Day 1 to Cycle 2 Day 1) and assessed by the Investigator as not being definitely attributable to underlying disease, disease progression, inter-current illness, concomitant medications or any other alternative cause.
Time frame: Day 1 through the first 28 days from the first dose of SNDX-6352 or administration of the third dose (Cycle 2 Day 1), whichever is later (from Cycle 1 Day 1 to Cycle 2 Day 1)
Phase 1: Recommended Phase 2 Dose (RP2D)
The RP2D was determined in discussion with the Sponsor, Medical Monitor, and Dose Determination Phase Investigators and was based on observations from the Phase 1 of the study (clinical benefit in chronic graft versus host disease \[cGVHD\] and pharmacokinetic/pharmacodynamic effects).
Time frame: Day 1 through the first 28 days from the first dose of SNDX-6352 or administration of the third dose (Cycle 2 Day 1), whichever is later (from C1D1 to C2D1)
Phase 2: Overall Response Rate (ORR) as Assessed by the Number of Participants With Complete Response (CR) or Partial Response (PR) at Cycle 7 Day 1 (Day 168)
CR or PR was defined by the 2014 National Institutes of Health (NIH) Consensus Development Project on Criteria for Clinical Trials in cGVHD.CR was defined as resolution of all manifestations in each organ or site, and PR was defined as improvement in at least 1 organ or site without progression in any other organ or site. ORR was defined as the percentage of participants achieving a best overall response of CR or PR .ORR calculated as: (number of participants with best overall response as CR or PR)/total number of participants.
Time frame: Cycle 7 Day 1 (Day 168)
Phase 1: Area Under the Plasma Concentration-time Curve From Time 0 to the Last Measurable Concentration for SNDX-6352
Blood samples were collected for determination of SNDX-6352 concentration.
Time frame: Cycle 1: predose, at 30 min (end of infusion), and at 1 hour and 8 hours on Day 1 and Day 15
Phase 1: Observed Maximum Plasma Concentration for SNDX-6352
Blood samples were collected for determination of SNDX-6352 concentration.
Time frame: Cycle 1: predose, at 30 min (end of infusion), and at 1 hour and 8 hours on Day 1 and Day 15
Phase 1: Time to Observed Maximum Plasma Concentration
Blood samples were collected for determination of SNDX-6352 concentration.
Time frame: Cycle 1: predose, at 30 min (end of infusion), and at 1 hour and 8 hours on Day 1 and Day 15
Phase 1: Changes From Baseline in Colony-Stimulating Factor-1 (CSF-1) and Interleukin (IL-34) Serum Concentrations
Blood samples were collected for determination of serum concentrations.
Time frame: Baseline, Cycle 1 Day 8, Day 15, predose at Cycle 2 Day 1, Cycle 4 Day 1 (28-day cycles), and end of treatment (EOT) (median duration of treatment = 7 months)
Phase 1: Percent Change From Baseline in Nonclassical Monocytes (CD14+CD16++)
Blood samples were collected for determination nonclassical monocytes levels.
Time frame: Baseline, Day 8, Day 15, predose at Cycle 2 Day 1, Cycle 4 Day 1, and EOT (median duration of treatment = 7 months)
Phase 1: Number of Participants Positive for Anti-Drug Antibodies (ADA)
Blood samples were collected for ADA assessment. A participant was considered ADA positive if at least 1 postbaseline sample was ADA positive.
Time frame: Predose on Cycle 1 Day 1, Cycle 1 Day 15, Cycle 3 Day 1, Day 1 of each subsequent cycle through EOT plus 30 days after last dose (safety follow-up) (median duration of treatment = 7 months)
Phase 2: Best Overall Response (BOR), as Defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD
Physician-reported global cGVHD activity assessment and cGVHD response determination. Best overall response was calculated as percent of participants with a response of CR or PR.
Time frame: Day 1 of each 28-Day cycle up to Cycle 7 Day 1
Phase 2: Failure Free Survival (FFS)
FFS was defined as the time from first dose of study intervention to unequivocal progression of cGVHD or relapse of underlying malignancy or addition of another systemic immune suppressive therapy or discontinuation of study treatment due to toxicity or death for any reason. Unequivocal progression of cGVHD is defined as treatment discontinuation due to clinical progression. The duration of FFS was evaluated using organ-specific cGVHD activity assessment form and and summarized descriptively using the Kaplan-Meier method.
Time frame: From first dose of study intervention (Day 1) up to 27 months
Phase 2: Duration of Response (DOR)
DOR was defined as the time of initial response until documented progression or start of another systemic treatment as assessed by the Kaplan-Meir method.
Time frame: Day 1 of each 28-Day cycle for up to 12 cycles
Phase 2: Sustained Response Rate (SRR)
SSR of CR or PR ≥20 weeks was defined as rate of CR or PR lasting for at least 20 weeks from the time of initial response.
Time frame: Day 1 of each 28-Day cycle for up to 12 cycles
Phase 2: Organ-specific Response Rate Based on 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD
The percentage of participants with a response (CR/PR) in the skin, eyes, mouth, esophagus, upper gastrointestinal (GI), lower GI, liver, lungs, or joints and fascia were assessed using the NIH Consensus Development Project on Clinical Trials.
Time frame: Day 1 of each 28-Day cycle for up to 12 cycles
Phase 2: Number of Participants With a Joint and Fascia Response Based on Refined NIH Response Algorithm for cGVHD
Time frame: Day 1 of each 28-Day cycle for up to 12 cycles
Phase 2: Number of Participants With A Lee Symptom Scale Summary Score Decrease of at Least 7 Points From Baseline
The Lee cGVHD symptom questionnaire asked participants to indicate the degree of "bother" that they experienced during the past 7 days due to symptoms in 7 domains potentially affected by chronic GVHD (skin, eyes and mouth, breathing, eating and digestion, muscles and joints, energy, emotional distress) using a 5-point Likert scale from 0 "not at all" to 4 "extremely." Scores were normalized (0 to 100 scale) and the number of participants with a ≥ 7-point decrease in normalized score was calculated. A decrease in score indicated improvement in symptoms.
Time frame: Day 1 of each 28-Day cycle for up to 12 cycles
Phase 2: Number of Participants With a ≥50% Reduction in Prednisone Equivalent Dosage Lasting at Least 28 Days
Time frame: Day 1 of each 28-Day cycle for up to 12 cycles
Phase 2: Number of Participants Who Discontinued Calcineurin Inhibitor Use
Time frame: Day 1 of each 28-Day cycle for up to 12 cycles
| Milestone | Phase 1 Dose Escalation: SNDX-6352 0.15 mg/kg Q2W | Phase 1 Dose Escalation: SNDX-6352 0.5 mg/kg Q2W | Phase 1 Dose Escalation: SNDX-6352 1 mg/kg Q2W | Phase 1 Dose Escalation: SNDX-6352 3 mg/kg Q2W | Phase 1 Dose Escalation: SNDX-6352 3 mg/kg Q4W | Phase 2 Dose Expansion: SNDX-6352 1 mg/kg Q2W |
|---|---|---|---|---|---|---|
| Started | 1 | 1 | 3 | 6 | 7 | 23 |
| Received at least 1 dose of study treatment | 1 | 1 | 3 | 6 | 6 | 23 |
| Dose-limiting toxicity (dlt) evaluable | 1 | 1 | 3 | 6 | 6 | 0 |
| Completed | 0 | 1 | 1 | 3 | 3 | 9 |
| Not completed | 1 | 0 | 2 | 3 | 4 | 14 |
| Withdrew: Investigator's decision | 0 | 0 | 0 | 1 | 0 | 7 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Progressive disease | 1 | 0 | 1 | 0 | 3 | 4 |
| Withdrew: Difficulty coming into site | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Death | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Drug intolerance | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Noncompliance with follow-up visit | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Not treated | 0 | 0 | 0 | 0 | 1 | 0 |
A DLT was defined as the occurrence of any protocol-specified event within the first 28 days from the first dose of SNDX-6352 or administration of the third dose (Cycle 2 Day 1), whichever is later (from Cycle 1 Day 1 to Cycle 2 Day 1) and assessed by the Investigator as not being definitely attributable to underlying disease, disease progression, inter-current illness, concomitant medications or any other alternative cause.
| Participants | Phase 1 Dose Escalation: SNDX-6352 0.15 mg/kg | Phase 1 Dose Escalation: SNDX-6352 0.5 mg/kg | Phase 1 Dose Escalation: SNDX-6352 1 mg/kg | Phase 1 Dose Escalation: SNDX-6352 3 mg/kg | Phase 1 Dose Escalation: SNDX-6352 3 mg/kg Q4W |
|---|---|---|---|---|---|
| Phase 1: Number of Participants With DLTs | 0 | 0 | 0 | 2 | 0 |
The RP2D was determined in discussion with the Sponsor, Medical Monitor, and Dose Determination Phase Investigators and was based on observations from the Phase 1 of the study (clinical benefit in chronic graft versus host disease \[cGVHD\] and pharmacokinetic/pharmacodynamic effects).
| mg/kg | Phase 1 Dose Determination:SNDX-6352 |
|---|---|
| Phase 1: Recommended Phase 2 Dose (RP2D) | 1 |
CR or PR was defined by the 2014 National Institutes of Health (NIH) Consensus Development Project on Criteria for Clinical Trials in cGVHD.CR was defined as resolution of all manifestations in each organ or site, and PR was defined as improvement in at least 1 organ or site without progression in any other organ or site. ORR was defined as the percentage of participants achieving a best overall response of CR or PR .ORR calculated as: (number of participants with best overall response as CR or PR)/total number of participants.
| percentage of participants | Phase 2 Dose Expansion: SNDX-6352 1 mg/kg Q2W |
|---|---|
| Phase 2: Overall Response Rate (ORR) as Assessed by the Number of Participants With Complete Response (CR) or Partial Response (PR) at Cycle 7 Day 1 (Day 168) | 39.1 (19.71 to 61.46) |
Blood samples were collected for determination of SNDX-6352 concentration.
| µg*h/mL | Phase 1 Dose Escalation: SNDX-6352 0.15 mg/kg Q2W | Phase 1 Dose Escalation: SNDX-6352 0.5 mg/kg Q2W | Phase 1 Dose Escalation: SNDX-6352 1 mg/kg Q2W | Phase 1 Dose Escalation: SNDX-6352 3 mg/kg Q2W | Phase 1 Dose Escalation: SNDX-6352 3 mg/kg Q4W |
|---|---|---|---|---|---|
| Cycle 1 Day 1 | 30.7 (30.7 to 30.7) | 96.2 (96.2 to 96.2) | 1546.0 (898.0 to 2140.0) | 10263.3 (4660.0 to 15300.0) | 12256.7 (6760.0 to 20700.0) |
| Cycle 1 Day 15 | 22.9 (22.9 to 22.9) | 98.9 (98.9 to 98.9) | 714.0 (121.0 to 1740.0) | 14,055.0 (575.0 to 26,900.0) | — |
Blood samples were collected for determination of SNDX-6352 concentration.
| µg/mL | Phase 1 Dose Escalation: SNDX-6352 0.15 mg/kg Q2W | Phase 1 Dose Escalation: SNDX-6352 0.5 mg/kg Q2W | Phase 1 Dose Escalation: SNDX-6352 1 mg/kg Q2W | Phase 1 Dose Escalation: SNDX-6352 3 mg/kg Q2W | Phase 1 Dose Escalation: SNDX-6352 3 mg/kg Q4W |
|---|---|---|---|---|---|
| Cycle 1 Day 1 | 4.6 (4.6 to 4.6) | 13.7 (13.7 to 13.7) | 26.7 (19.5 to 38.7) | 84.0 (63.0 to 106.0) | 82.2 (62.2 to 104.0) |
| Cycle 1 Day 15 | 3.5 (3.5 to 3.5) | 14.2 (14.2 to 14.2) | 27.4 (20.1 to 41.3) | 91.8 (65.1 to 132.0) | — |
Blood samples were collected for determination of SNDX-6352 concentration.
| hours | Phase 1 Dose Escalation: SNDX-6352 0.15 mg/kg Q2W | Phase 1 Dose Escalation: SNDX-6352 0.5 mg/kg Q2W | Phase 1 Dose Escalation: SNDX-6352 1 mg/kg Q2W | Phase 1 Dose Escalation: SNDX-6352 3 mg/kg Q2W | Phase 1 Dose Escalation: SNDX-6352 3 mg/kg Q4W |
|---|---|---|---|---|---|
| Cycle 1 Day 1 | 1.0 (1.0 to 1.0) | 1.5 (1.5 to 1.5) | 0.6 (0.6 to 0.6) | 0.9 (0.6 to 7.5) | 1.0 (0.5 to 7.9) |
| Cycle 1 Day 15 | 0.6 (0.6 to 0.6) | 0.5 (0.5 to 0.5) | 1.0 (0.6 to 1.5) | 1.0 (0.6 to 1.1) | — |
Blood samples were collected for determination of serum concentrations.
| pg/mL | Phase 1 Dose Escalation: SNDX-6352 0.15 mg/kg Q2W | Phase 1 Dose Escalation: SNDX-6352 0.5 mg/kg Q2W | Phase 1 Dose Escalation: SNDX-6352 1 mg/kg Q2W | Phase 1 Dose Escalation: SNDX-6352 3 mg/kg Q2W | Phase 1 Dose Escalation: SNDX-6352 3 mg/kg Q4W |
|---|---|---|---|---|---|
| CSF-1 Cycle 1 Day 8 | 2.0 (2 to 2) | 602.0 (602 to 602) | 364480.0 (211185 to 400666) | 544837.5 (433627 to 613511) | 451482.0 (366543 to 697378) |
| CSF-1 Cycle 1 Day 15 | 69.0 (69 to 69) | -87.0 (-87 to -87) | 680.0 (-418 to 1556) | 897522.0 (75411 to 966627) | 821180.5 (581543 to 990015) |
| CSF-1 Cycle 2 Day 1 | 19.0 (19 to 19) | 227.0 (227 to 227) | 400.0 (-126 to 60066) | 1474438.5 (1439355 to 1509522) | 773476.0 (11 to 1029015) |
| CSF-1 Cycle 4 Day 1 | — | 229.0 (229 to 229) | 465.0 (-319 to 1378480) | 899337.5 (-680 to 1799355) | 1386196.5 (603378 to 2169015) |
| CSF-1 EOT | 63.0 (63 to 63) | — | — | — | 1709787.0 (1709787 to 1709787) |
| IL-34 Cycle 1 Day 8 | 0 (0 to 0) | 0 (0 to 0) | 156.7 (86 to 409) | 576.2 (316 to 929) | 286.7 (81 to 775) |
| IL-34 Cycle 1 Day 15 | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 690.7 (199 to 1259) | 456.7 (216 to 744) |
| IL-34 Cycle 2 Day 1 | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 42) | 1133.7 (979 to 1289) | 190.7 (0 to 931) |
| IL-34 Cycle 4 Day 1 | — | 0 (0 to 0) | 0 (0 to 395) | 569.4 (0 to 1139) | 533.7 (241 to 827) |
| IL-34 EOT | 0 (0 to 0) | — | — | — | 676.7 (676.7 to 676.7) |
Blood samples were collected for determination nonclassical monocytes levels.
| percent change | Phase 1 Dose Escalation: SNDX-6352 0.15 mg/kg Q2W | Phase 1 Dose Escalation: SNDX-6352 0.5 mg/kg Q2W | Phase 1 Dose Escalation: SNDX-6352 1 mg/kg Q2W | Phase 1 Dose Escalation: SNDX-6352 3 mg/kg Q2W | Phase 1 Dose Escalation: SNDX-6352 3 mg/kg Q4W |
|---|---|---|---|---|---|
| Cycle 1 Day 8 | — | -41.7 (-41.7 to -41.7) | -92.7 (-97 to -89) | -95.7 (-98 to -90) | -81.4 (-90 to -33) |
| Cycle 1 Day 15 | — | -66.7 (-66.7 to -66.7) | 242.8 (-31 to 517) | -96.5 (-98 to -94) | -81.5 (-84 to 67) |
| Cycle 1 Day 22 | — | — | — | — | -90.9 (-90.9 to -90.9) |
| Cycle 2 Day 1 | — | -58.3 (-58.3 to -58.3) | -31.0 (-31.0 to -31.0) | -94.4 (-94.4 to -94.4) | -67.5 (-81 to 167) |
| Cycle 4 Day 1 | — | -16.7 (-16.7 to -16.7) | 273.5 (41 to 506) | -76.5 (-99 to -54) | -82.5 (-91 to -74) |
| EOT | — | — | — | — | -75.0 (-75.0 to -75.0) |
Blood samples were collected for ADA assessment. A participant was considered ADA positive if at least 1 postbaseline sample was ADA positive.
| Participants | Phase 1 Dose Escalation: SNDX-6352 0.15 mg/kg Q2W | Phase 1 Dose Escalation: SNDX-6352 0.5 mg/kg Q2W | Phase 1 Dose Escalation: SNDX-6352 1 mg/kg Q2W | Phase 1 Dose Escalation: SNDX-6352 3 mg/kg Q2W | Phase 1 Dose Escalation: SNDX-6352 3 mg/kg Q4W |
|---|---|---|---|---|---|
| Phase 1: Number of Participants Positive for Anti-Drug Antibodies (ADA) | 0 | 0 | 1 | 3 | 2 |
Physician-reported global cGVHD activity assessment and cGVHD response determination. Best overall response was calculated as percent of participants with a response of CR or PR.
| percentage of participants | Phase 2 Dose Expansion: SNDX-6352 1 mg/kg Q2W |
|---|---|
| Phase 2: Best Overall Response (BOR), as Defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD | 78.3 (56.3 to 92.54) |
FFS was defined as the time from first dose of study intervention to unequivocal progression of cGVHD or relapse of underlying malignancy or addition of another systemic immune suppressive therapy or discontinuation of study treatment due to toxicity or death for any reason. Unequivocal progression of cGVHD is defined as treatment discontinuation due to clinical progression. The duration of FFS was evaluated using organ-specific cGVHD activity assessment form and and summarized descriptively using the Kaplan-Meier method.
| months | Phase 2 Dose Expansion: SNDX-6352 1 mg/kg Q2W |
|---|---|
| Phase 2: Failure Free Survival (FFS) | 16.9 (9.3 to NA) |
DOR was defined as the time of initial response until documented progression or start of another systemic treatment as assessed by the Kaplan-Meir method.
| months | Phase 2 Dose Expansion: SNDX-6352 1 mg/kg Q2W |
|---|---|
| Phase 2: Duration of Response (DOR) | 9.53 (1.87 to 17.05) |
SSR of CR or PR ≥20 weeks was defined as rate of CR or PR lasting for at least 20 weeks from the time of initial response.
| percentage of participants | Phase 2 Dose Expansion: SNDX-6352 1 mg/kg Q2W |
|---|---|
| Phase 2: Sustained Response Rate (SRR) | 39.1 (19.7 to 61.5) |
The percentage of participants with a response (CR/PR) in the skin, eyes, mouth, esophagus, upper gastrointestinal (GI), lower GI, liver, lungs, or joints and fascia were assessed using the NIH Consensus Development Project on Clinical Trials.
| percentage of participants | Phase 2 Dose Expansion: SNDX-6352 1 mg/kg Q2W |
|---|---|
| Esophagus | 83.3 (35.88 to 99.58) |
| Eyes | 18.8 (4.05 to 45.65) |
| Joints and Fascia | 76.5 (50.1 to 93.19) |
| Liver | 0 (0 to 70.76) |
| Lower GI | 100.0 (39.76 to 100) |
| Lungs | 33.3 (7.49 to 70.07) |
| Mouth | 75.0 (42.81 to 94.51) |
| Skin | 19.0 (5.45 to 41.91) |
| Upper GI | 100.0 (39.76 to 100) |
| Global | 47.8 (26.82 to 69.41) |
| Participants | Phase 2 Dose Expansion: SNDX-6352 1 mg/kg Q2W |
|---|---|
| Improved | 10 |
| Stable | 7 |
The Lee cGVHD symptom questionnaire asked participants to indicate the degree of "bother" that they experienced during the past 7 days due to symptoms in 7 domains potentially affected by chronic GVHD (skin, eyes and mouth, breathing, eating and digestion, muscles and joints, energy, emotional distress) using a 5-point Likert scale from 0 "not at all" to 4 "extremely." Scores were normalized (0 to 100 scale) and the number of participants with a ≥ 7-point decrease in normalized score was calculated. A decrease in score indicated improvement in symptoms.
| Participants | Phase 2 Dose Expansion: SNDX-6352 1 mg/kg Q2W |
|---|---|
| Phase 2: Number of Participants With A Lee Symptom Scale Summary Score Decrease of at Least 7 Points From Baseline | 12 |
| Participants | Phase 2 Dose Expansion: SNDX-6352 1 mg/kg Q2W |
|---|---|
| Phase 2: Number of Participants With a ≥50% Reduction in Prednisone Equivalent Dosage Lasting at Least 28 Days | 5 |
| Participants | Phase 2 Dose Expansion: SNDX-6352 1 mg/kg Q2W |
|---|---|
| Phase 2: Number of Participants Who Discontinued Calcineurin Inhibitor Use | 0 |
Collected over From first dose of study drug up to EOT plus 90 days after last dose (safety follow-up) (median duration of treatment = 7 months). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SNDX-6352 0.15 mg/kg Q2W | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) |
| SNDX-6352 0.5 mg/kg Q2W | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) |
| SNDX-6352 1 mg/kg Q2W | 1/26 (3.8%) | 12/26 (46.2%) | 26/26 (100%) |
| SNDX-6352 3 mg/kg Q2W | 0/6 (0%) | 3/6 (50%) | 6/6 (100%) |
| SNDX-6352 3 mg/kg Q4W | 0/6 (0%) | 2/6 (33.3%) | 6/6 (100%) |
| Event | SNDX-6352 0.15 mg/kg Q2W | SNDX-6352 0.5 mg/kg Q2W | SNDX-6352 1 mg/kg Q2W | SNDX-6352 3 mg/kg Q2W | SNDX-6352 3 mg/kg Q4W |
|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 0/1 | 1/1 | 3/26 | 0/6 | 0/6 |
| HepatitisHepatobiliary disorders | 1/1 | 0/1 | 0/26 | 0/6 | 0/6 |
| Spinal fractureInjury, poisoning and procedural complications | 0/1 | 1/1 | 0/26 | 0/6 | 0/6 |
| CellulitisInfections and infestations | 0/1 | 0/1 | 0/26 | 1/6 | 1/6 |
| PyrexiaGeneral disorders | 0/1 | 0/1 | 1/26 | 1/6 | 0/6 |
| Abdominal painGastrointestinal disorders | 0/1 | 0/1 | 0/26 | 0/6 | 1/6 |
| Acute kidney injuryRenal and urinary disorders | 0/1 | 0/1 | 0/26 | 1/6 | 0/6 |
| BronchiectasisRespiratory, thoracic and mediastinal disorders | 0/1 | 0/1 | 0/26 | 0/6 | 1/6 |
| BronchitisInfections and infestations | 0/1 | 0/1 | 0/26 | 0/6 | 1/6 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/1 | 0/1 | 0/26 | 0/6 | 1/6 |
| Event | SNDX-6352 0.15 mg/kg Q2W | SNDX-6352 0.5 mg/kg Q2W | SNDX-6352 1 mg/kg Q2W | SNDX-6352 3 mg/kg Q2W | SNDX-6352 3 mg/kg Q4W |
|---|---|---|---|---|---|
| FatigueGeneral disorders | 0/1 | 1/1 | 12/26 | 3/6 | 2/6 |
| Oedema peripheralGeneral disorders | 1/1 | 0/1 | 4/26 | 1/6 | 2/6 |
| MalaiseGeneral disorders | 1/1 | 0/1 | 1/26 | 2/6 | 0/6 |
| Aspartate aminotransferase increasedInvestigations | 1/1 | 0/1 | 6/26 | 4/6 | 4/6 |
| Blood creatine phosphokinase increasedInvestigations | 0/1 | 0/1 | 3/26 | 6/6 | 5/6 |
| Alanine aminotransferase increasedInvestigations | 1/1 | 0/1 | 5/26 | 4/6 | 3/6 |
| Blood lactate dehydrogenase increasedInvestigations | 0/1 | 1/1 | 4/26 | 4/6 | 3/6 |
| Amylase increasedInvestigations | 1/1 | 0/1 | 6/26 | 4/6 | 0/6 |
| Gamma-glutamyltransferase increasedInvestigations | 1/1 | 0/1 | 2/26 | 1/6 | 1/6 |
| Blood alkaline phosphatase increasedInvestigations | 1/1 | 0/1 | 2/26 | 1/6 | 0/6 |
Safety Analysis Set: All participants who received at least 1 dose of study treatment.
| Age, Continuous(years) | Phase 1 Dose Escalation: SNDX-6352 0.15 mg/kg Q2W | Phase 1 Dose Escalation: SNDX-6352 0.5 mg/kg Q2W | Phase 1 Dose Escalation: SNDX-6352 1 mg/kg Q2W | Phase 1 Dose Escalation: SNDX-6352 3 mg/kg Q2W | Phase 1 Dose Escalation: SNDX-6352 3 mg/kg Q4W | Phase 2 Dose Expansion: SNDX-6352 1 mg/kg Q2W | Total |
|---|---|---|---|---|---|---|---|
| Mean | 64.0 (64 to 64) | 48.0 (48 to 48) | 43.7 (29 to 66) | 61.0 (53 to 73) | 59.2 (31 to 73) | 52.5 (16 to 69) | 54.7 (16 to 73) |
| Sex: Female, Male(Participants) | Phase 1 Dose Escalation: SNDX-6352 0.15 mg/kg Q2W | Phase 1 Dose Escalation: SNDX-6352 0.5 mg/kg Q2W | Phase 1 Dose Escalation: SNDX-6352 1 mg/kg Q2W | Phase 1 Dose Escalation: SNDX-6352 3 mg/kg Q2W | Phase 1 Dose Escalation: SNDX-6352 3 mg/kg Q4W | Phase 2 Dose Expansion: SNDX-6352 1 mg/kg Q2W | Total |
|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 1 | 3 | 2 | 9 | 15 |
| Male | 1 | 1 | 2 | 3 | 4 | 14 | 25 |
| Ethnicity (NIH/OMB)(Participants) | Phase 1 Dose Escalation: SNDX-6352 0.15 mg/kg Q2W | Phase 1 Dose Escalation: SNDX-6352 0.5 mg/kg Q2W | Phase 1 Dose Escalation: SNDX-6352 1 mg/kg Q2W | Phase 1 Dose Escalation: SNDX-6352 3 mg/kg Q2W | Phase 1 Dose Escalation: SNDX-6352 3 mg/kg Q4W | Phase 2 Dose Expansion: SNDX-6352 1 mg/kg Q2W | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 1 | 1 | 3 | 6 | 6 | 22 | 39 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | Phase 1 Dose Escalation: SNDX-6352 0.15 mg/kg Q2W | Phase 1 Dose Escalation: SNDX-6352 0.5 mg/kg Q2W | Phase 1 Dose Escalation: SNDX-6352 1 mg/kg Q2W | Phase 1 Dose Escalation: SNDX-6352 3 mg/kg Q2W | Phase 1 Dose Escalation: SNDX-6352 3 mg/kg Q4W | Phase 2 Dose Expansion: SNDX-6352 1 mg/kg Q2W | Total |
|---|---|---|---|---|---|---|---|
| Race — Black or African American | 1 | 0 | 0 | 1 | 1 | 2 | 5 |
| Race — White | 0 | 1 | 3 | 5 | 5 | 20 | 34 |
| Race — Other | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2018 to primary completion in Aug 2022, 45 months.
Results were first posted in Nov 2024, 2 years 3 months after primary completion. A results delay was requested in Aug 2023.
Of 24 phase 1/2 interventional studies under Bronchiolitis Obliterans Syndrome, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 87. This study's 45 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Axatilimab
Bronchiolitis Obliterans Syndrome →